"51716 Hydroquinone and Alternative Agents for Hyperpigmentation: A Sys" by Kavya Shivaram, Katherine Edwards et al.
 

51716 Hydroquinone and Alternative Agents for Hyperpigmentation: A Systematic Review

Document Type

Conference Proceeding

Publication Date

9-1-2024

Publication Title

J Am Acad Dermatol

Abstract

Background: Hydroquinone has been used for years for multiple conditions, including melasma, post inflammatory hyperpigmentation, dyschromia from photoaging, and solar lentigines. It is known to be a very effective lightening agent, but several concerns have been raised about its use. The recent U.S. ban on OTC skin lightening products containing hydroquinone has prompted further questioning of the safety of this widely used agent. We aim to provide an updated review of the safety profile of hydroquinone and evaluate the efficacy and safety of alternative lightening agents. Methods: A literature search was conducted using the electronic databases Medline and Embase with search terms ‘hydroquinone’, ‘safety’, ‘skin pigmentation’, and ‘skin lightening preparations’. The search yielded 137 results that were then screened. Results: Common adverse effects from hydroquinone use including irritant contact dermatitis, hypopigmentation, and postinflammatory hyperpigmentation were found to be tolerable and often transient in treated patients. Ochronosis and ocular complications are chronic adverse effects that are associated with long-term hydroquinone use without medical supervision. Alternative lightening agents including mequinol, arbutin, kojic acid, and others have shown comparable efficacy to hydroquinone in treating hyperpigmentation with less concerning side effects. Conclusion: Recent studies of hydroquinone further impress its efficacy and safety when used as directed and under medical supervision. Groups who may be susceptible to increased hydroquinone sensitivity or unable to withstand its adverse effects may benefit from using alternative skin lightening agents listed in this review with higher safety profiles.

Volume

91

Issue

3

First Page

AB229

Share

COinS